Perrigo Company plc Business Acquisition, Pro Forma Revenue
Perrigo Company plc (PRGO) reported Business Acquisition, Pro Forma Revenue of $4.75 billion for the 12-month period ending 2022-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2025-02-28
- Perrigo Company plc business acquisition, pro forma revenue for the quarter ending 2022-12-31 was $1.17B.
- Perrigo Company plc business acquisition, pro forma revenue for the quarter ending 2022-10-01 was $1.16B, a 2.97% increase year-over-year.
- Perrigo Company plc business acquisition, pro forma revenue for the quarter ending 2022-07-02 was $1.21B, a 12.85% increase year-over-year.
- Perrigo Company plc business acquisition, pro forma revenue for the quarter ending 2022-04-02 was $1.21B.
- Perrigo Company plc business acquisition, pro forma revenue for fiscal 2022 was $4.75B.
- Perrigo Company plc business acquisition, pro forma revenue for fiscal 2020 was $5.11B, a 0.02% decline from fiscal 2019.
- Perrigo Company plc business acquisition, pro forma revenue for fiscal 2019 was $5.11B, a 1.86% increase from fiscal 2018.
- Perrigo Company plc business acquisition, pro forma revenue for fiscal 2018 was $5.02B.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 3 month as first filed | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 6 month as first filed | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 9 month as first filed | Business Acquisition, Pro Forma Revenue 12 month | Business Acquisition, Pro Forma Revenue 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2022-12-31 | $1.17B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $2.33B derived: sum of 2 quarters · filed 2025-02-28 | $3.54B derived: sum of 3 quarters · filed 2025-02-28 | $4.75B 10-K · filed 2025-02-28 | ||||
| 2022-10-01 | $1.16B 10-Q · filed 2023-11-07 | $1.10B 10-Q · filed 2022-11-08 | $2.36B derived: sum of 2 quarters · filed 2023-11-07 | $3.57B 10-Q · filed 2023-11-07 | $3.40B 10-Q · filed 2022-11-08 | |||
| 2022-07-02 | $1.21B 10-Q · filed 2023-08-08 | $1.15B 10-Q · filed 2022-08-09 | $2.42B 10-Q · filed 2023-08-08 | $2.30B 10-Q · filed 2022-08-09 | ||||
| 2022-04-02 | $1.21B 10-Q · filed 2023-05-09 | |||||||
| 2021-10-02 | $1.12B 10-Q · filed 2022-11-08 | $2.19B derived: sum of 2 quarters · filed 2022-11-08 | $3.27B 10-Q · filed 2022-11-08 | |||||
| 2021-07-03 | $1.07B 10-Q · filed 2022-08-09 | $2.15B 10-Q · filed 2022-08-09 | ||||||
| 2020-12-31 | $2.03B derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $3.04B derived: sum of 2 quarters · filed 2021-11-12 | $3.99B derived: sum of 3 quarters · filed 2021-11-12 | $5.11B 10-K · filed 2021-03-01 | ||||
| 2020-09-26 | $1.01B 10-Q · filed 2021-11-12 | $1.21B 10-Q · filed 2020-11-05 | $1.96B derived: sum of 2 quarters · filed 2021-11-12 | $3.08B 10-Q · filed 2021-11-12 | $3.80B 10-Q · filed 2020-11-05 | $4.46B derived: sum of 4 quarters · filed 2021-11-12 | ||
| 2020-06-27 | $955.00M 10-Q · filed 2021-08-11 | $1.22B 10-Q · filed 2020-08-05 | $2.07B 10-Q · filed 2021-08-11 | $2.59B 10-Q · filed 2020-08-05 | $3.45B derived: sum of 3 quarters · filed 2021-08-11 | $4.67B derived: sum of 4 quarters · filed 2021-08-11 | ||
| 2020-03-28 | $1.12B 10-Q · filed 2021-05-12 | $2.50B derived: sum of 2 quarters · filed 2021-05-12 | $3.72B derived: sum of 3 quarters · filed 2021-05-12 | $4.96B derived: sum of 4 quarters · filed 2021-05-12 | ||||
| 2019-12-31 | $1.38B derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $2.60B derived: sum of 2 quarters · filed 2021-03-01 | $3.84B derived: sum of 3 quarters · filed 2021-03-01 | $5.11B 10-K · filed 2021-03-01 | ||||
| 2019-09-28 | $1.22B 10-Q · filed 2020-11-05 | $2.46B derived: sum of 2 quarters · filed 2020-11-05 | $3.73B 10-Q · filed 2020-11-05 | |||||
| 2019-06-29 | $1.24B 10-Q · filed 2020-08-05 | $2.52B 10-Q · filed 2020-08-05 | ||||||
| 2018-12-31 | $5.02B 10-K · filed 2021-03-01 | |||||||
| 2016-12-31 | $1.33B derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-01 | $2.60B derived: sum of 2 quarters · filed 2018-03-01 | $3.94B derived: sum of 3 quarters · filed 2018-03-01 | $5.29B 10-K · filed 2018-03-01 | ||||
| 2016-10-01 | $1.27B 10-Q/A · filed 2017-05-23 | $1.36B 10-Q · filed 2016-11-10 | $2.61B derived: sum of 2 quarters · filed 2017-05-23 | $3.96B 10-Q/A · filed 2017-05-23 | $4.24B 10-Q · filed 2016-11-10 | $5.35B derived: sum of 4 quarters · filed 2018-03-01 | ||
| 2016-07-02 | $1.34B 10-Q/A · filed 2017-05-22 | $1.48B 10-Q · filed 2016-08-10 | $2.69B 10-Q/A · filed 2017-05-22 | $2.87B 10-Q · filed 2016-08-10 | $4.08B derived: sum of 3 quarters · filed 2018-03-01 | $5.44B derived: sum of 4 quarters · filed 2018-03-01 | ||
| 2016-04-02 | $1.35B 10-Q/A · filed 2017-05-22 | $1.39B 10-Q · filed 2016-05-16 | $2.74B derived: sum of 2 quarters · filed 2018-03-01 | $4.10B derived: sum of 3 quarters · filed 2018-03-01 | $5.61B derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2015-12-31 | $1.39B derived: 10-K 6 month − 10-Q/A 3 month · filed 2018-03-01 | $2.75B 10-K · filed 2018-03-01 | $2.85B 10-KT · filed 2016-02-25 | $4.26B derived: sum of 3 quarters · filed 2018-03-01 | $5.56B derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2015-09-26 | $1.36B 10-Q/A · filed 2017-05-23 | $1.43B 10-Q · filed 2016-11-10 | $2.87B derived: sum of 2 quarters · filed 2017-05-23 | $4.17B 10-Q/A · filed 2017-05-23 | $4.45B 10-Q · filed 2016-11-10 | |||
| 2015-06-27 | $1.51B 10-Q/A · filed 2017-05-22 | $1.63B 10-Q · filed 2016-08-10 | $2.81B 10-Q/A · filed 2017-05-22 | $3.01B 10-Q · filed 2016-08-10 | $5.68B 10-K · filed 2018-03-01 | $5.67B 10-K · filed 2015-08-13 | ||
| 2015-03-28 | $1.30B 10-Q/A · filed 2017-05-22 | $1.38B 10-Q · filed 2016-05-16 | ||||||
| 2014-06-28 | $2.01B derived: 10-KT 12 month − 10-K 9 month · filed 2016-02-25 | $6.20B 10-KT · filed 2016-02-25 | $5.82B 10-K · filed 2015-08-13 | |||||
| 2014-03-29 | $4.19B 10-K · filed 2014-08-14 | |||||||
| 2013-03-30 | $3.67B 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |